OVERALL survival in the Asia cohort of the Phase III MARIPOSA study has been reported to favor amivantamab combined with lazertinib compared with osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Investigators noted that median survival is projected to exceed four years with the chemotherapy-free combination, representing an improvement of more than one year over osimertinib.
The MARIPOSA study is a randomized Phase III trial enrolling 1,074 patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations. The primary endpoint was progression-free survival by blinded independent central review, with overall survival as a key secondary endpoint. In the Asia subgroup, where EGFR-mutated NSCLC prevalence reaches 30 to 40%, the combination therapy met the prespecified endpoint of overall survival and demonstrated a statistically significant and clinically meaningful benefit.
Study investigators emphasized the importance of first-line therapy selection, as approximately 30% of patients do not proceed to second-line treatment due to rapid disease progression or health system limitations. Fewer than one in five patients with EGFR-mutated NSCLC remain alive at 5 years following diagnosis. According to the report, outcomes in the Asia cohort highlight the potential impact of first-line therapeutic choices in extending survival in this high-prevalence population.
The safety profile of amivantamab plus lazertinib was consistent with earlier analyses, with no new signals emerging during extended follow-up. Prior studies have suggested that prophylactic measures can help mitigate treatment-related adverse events, including dermatologic and infusion-related reactions as well as venous thromboembolism.
Overall survival findings from the Asia cohort will be presented at an upcoming congress. The combination of amivantamab and lazertinib has received regulatory approval in the United States, Europe, and several Asia-Pacific markets as a first-line treatment option for patients with EGFR-mutated NSCLC, based on results from the global MARIPOSA study.
Reference: Johnson & Johnson. Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer. September 12, 2025. Available at: https://www.jnj.com/media-center/press-releases/asia-cohort-of-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-achieved-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-versus-osimertinib-in-egfr-mutated-non-small-cell-lung-cancer. Last accessed: September 12, 2025.
